GILD

Gilead Sciences
D

GILD

106.460
USD
-0.26
(-0.24%)
مفتوح الان
حجم التداول
19,403
الربح لكل سهم
8
العائد الربحي
2.9
P/E
22
حجم السوق
132,565,526,425
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 6 أشهر
buy
2024-10-30 09:50
GILD Chart
المزيد
أصول ذات صلة
ABBV
ABBV
0.000
(0.00%)
182.870 USD
AMGN
AMGN
0.01
(0.00%)
271.95 USD
BIIB
BIIB
-1.200
(-0.95%)
125.090 USD
INCY
INCY
-0.660
(-1.02%)
63.840 USD
MRK
MRK
-0.240
(-0.31%)
77.480 USD
NVS
NVS
-0.290
(-0.26%)
112.180 USD
PFE
PFE
-0.080
(-0.34%)
23.125 USD
REGN
REGN
-8.90
(-1.49%)
587.75 USD
SNY
SNY
-0.380
(-0.72%)
51.940 USD
المزيد
الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).